Biotech Hangout cover image

Episode 76

Biotech Hangout

00:00

Merck Keynote 671 Study and Overall Survival in Lung Cancer

Discussion on the Merck Keynote 671 study, focusing on resectable lung cancer at stage 2, 3A, or 3B. The study reveals that giving Keytruda before surgical resection has shown an overall survival advantage, marking a significant development in neo-adjuvant studies with a PD-1 in lung cancer.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app